ArticleAdvances in therapy2026
CONTROL-IHD Study: 24-h BP Control with Metoprolol-Telmisartan FDC in Hypertension and Stable Ischemic Disease.
Article in Advances in therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionOptimal blood pressure (BP) control is essential in ischemic heart disease (IHD) to reduce cardiovascular risk. Current guidelines recommend fixed-dose combinations (FDCs) to enhance efficacy, patient adherence, and compliance. The study aimed to evaluate the efficacy and tolerability of metoprolol succinate extended-release 25/50 mg and telmisartan 40 mg FDC (Metosartan®) in patients with essential hypertension and stable IHD, using ambulatory BP monitoring (ABPM).
methodsThis open-label, single-arm, multicentric, Phase IV study enrolled 88 patients who received Metosartan® once daily (OD) for 8 weeks. Primary endpoint was change in mean 24-h systolic and diastolic BP (SBP, DBP) on ABPM from baseline to week 8. Secondary endpoints included responder rates, changes in mean heart rate (HR), short-term BP variability (BPV), 24-h distribution of BP reduction, and safety outcomes.
resultsSeventy-two patients completed the study. The FDC significantly reduced 24-h mean ABPM-measured SBP (143.38 ± 12.55 mmHg to 129.03 ± 11.77 mmHg) and DBP (88.84 ± 8.12 mmHg to 79.34 ± 7.93 mmHg) over 8 weeks. Mean reductions were - 14.41 ± 14.69 mmHg and - 9.52 ± 9.96 mmHg, for SBP and DBP, respectively (p < 0.0001). The ABPM-based responder rate was 36.62% (26/71). HR and 24-h BP indices improved significantly. From Weeks 2-4 to Week 8, the smoothness index increased by 0.15 (SBP) and 0.11 (DBP), while the treatment on variability index increased (TOVI) by 0.20 (SBP) and 0.16 (DBP) (all p < 0.0001). Short-term BPV showed mixed findings. Treatment was well tolerated, with only mild adverse events reported.
conclusionMetosartan® demonstrated effective and sustained 24-h BP reduction and good tolerability in Indian patients with hypertension and stable IHD. The reductions observed during the early post-application and late dosing-interval periods suggest sustained BP lowering over 24 h.
trial registrationClinical Trials Registry India, CTRI/2022/09/045464.
Indexed as
Identifiers
42742893What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.